Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: A post hoc analysis of the LOTUS trial

Current Medical Research and Opinion

Volumn 31, Issue 1, 2015, Pages 65-73

  Lundell, Lars ^a   Hatlebakk, Jan ^b   Galmiche, Jean Paul ^c   Attwood, Stephen E ^d   Ell, Christian ^e   Fiocca, Roberto ^f   Persson, Tore ^g   Nagy, Péter ^g   Eklund, Stefan ^g   Lind, Tore ^g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITÉ DE NANTES   (France)

^d NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY OF GENOA   (Italy)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Enterochromaffin cells; Gastritis; Gastroesophageal reflux; Helicobacter pylori; Long term care; Proton pump inhibitors; Safety

Indexed keywords

CHROMOGRANIN A; ESOMEPRAZOLE; GASTRIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ESOPHAGEAL PH MONITORING; ESOPHAGUS; FEMALE; FOLLOW UP; GASTRIC MUCOSAL ATROPHY; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HELICOBACTER INFECTION; HUMAN; INTESTINE METAPLASIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PHYSICIAN; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK FACTOR; SIDE EFFECT; SMOKING; STOMACH ATROPHY; TREATMENT DURATION; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; COMPLICATION; HEALTH STATUS; TIME; TREATMENT OUTCOME;

ADULT; AGED; ENDOSCOPY, GASTROINTESTINAL; ESOMEPRAZOLE; ESOPHAGEAL PH MONITORING; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84918791794     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.980500     Document Type: Article

References (20)

1. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, et al. The Montreal definition and classification of gastro-esophageal reflux disease (GERD) - a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20
2. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305:1969-77
3. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastrooesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008;57:1207-13
4. Shaheen NJ. Highlights from the new ACG guidelines for the diagnosis and management of GERD. Gastroenterol Hepatol (NY) 2013;9:377-9
5. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16
6. Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012;36:959-71
7. Price AB. The Sydney System: histological division. J Gastroenterol Hepatol 1991;6:209-22
8. Dimenäs E, Glise H, Hallerbäck B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046-52
9. Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 1998;7:75-83
10. Wiklund I, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg 1998;12(Suppl 583):41-9
11. Rohss K, Wilder-Smith C, Naucler E, et al. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004;24:1-7
12. Hatlebakk J, Zerbib F, Bonavina L, et al. Control of acid reflux 5 years after laparoscopic anti-reflux surgery (LARS) compared to long-term treatment with esomeprazole 20-40 mg daily (ESO) in the lotus study. Gut 2010;59:A87
13. Boeckxstaens G, El-Serag HB, Smout AJ, et al. Symptomatic reflux disease: the present, the past and the future. Gut 2014;63:1185-93
14. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010;32:720-37
15. Nilsson M, Johnsen R, Ye W, et al. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut 2004;53:1730-5
16. Locke GRR, Talley NJ, Fett SL, et al. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999;106:642-9
17. Vela MF. Medical treatments of GERD: the old and new. Gastroenterol Clin North Am 2014;43:121-33
18. Kandulski A, Malfertheiner P. Helicobacter pylori and gastroesophageal reflux disease. Curr Opin Gastroenterol 2014;30:402-7
19. Ghoshal UC, Chourasia D. Gastroesophageal reflux disease and Helicobacter pylori: what may be the relationship? J Neurogastroenterol Motil 2010;16:243-50
20. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55